EGLN2 and myeloid sarcoma: Another six investigated gene variants—RAB4B-EGLN2 rs111833532, CDKN1A rs3176326 and rs3176336, MAP1B rs1217817, DYSF–ZNF638 locus rs10191329 and MTSS1 rs9643199—did not show significant associations with the progressive MS phenotype (Table 2).